Dr. Pegram on Pertuzumab Combination for HER2-Positive Breast Cancer

Mark D. Pegram, MD
Published: Thursday, Aug 10, 2017



Mark D. Pegram, MD, director of the Breast Cancer Oncology Program at Stanford Medicine, discusses pertuzumab (Perjeta) plus trastuzumab (Herceptin) and chemotherapy for patients with HER2-positive breast cancer.

Based on level 1 evidence, there is good data to support the use of pertuzumab in combination with trastuzumab and chemotherapy in the first-line setting. That’s usually followed by ado-trastuzumab emtansine (T-DM1; Kadcyla) in the second-line setting, based on the pivotal EMILIA trial, explains Pegram.

Although EMILIA was not conducted in the pertuzumab metastatic breast cancer era, it is still assumed that T-DM1 will retain activity, states Pegram.
 


Mark D. Pegram, MD, director of the Breast Cancer Oncology Program at Stanford Medicine, discusses pertuzumab (Perjeta) plus trastuzumab (Herceptin) and chemotherapy for patients with HER2-positive breast cancer.

Based on level 1 evidence, there is good data to support the use of pertuzumab in combination with trastuzumab and chemotherapy in the first-line setting. That’s usually followed by ado-trastuzumab emtansine (T-DM1; Kadcyla) in the second-line setting, based on the pivotal EMILIA trial, explains Pegram.

Although EMILIA was not conducted in the pertuzumab metastatic breast cancer era, it is still assumed that T-DM1 will retain activity, states Pegram.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of CancersMay 30, 20181.5
Publication Bottom Border
Border Publication
x